Heat Biologics, Inc. (Heat Biologics) is a development-stage biopharmaceutical company engaged in the development of allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. Its ImmunePan Antigen Cytotoxic Therapy (ImPACT) is being designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to pump out a range of cancer-associated antigens together with a immune adjuvant called gp96 to educate and activate a cancer patient�s immune system to recognize and kill cancerous cells. Its primary product candidates are HS-110 and HS-410. It is also developing ImPACT therapeutic vaccines for breast cancer and ovarian cancer.